CME credits: 1.00

Valid until: 22-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutics-in-adh1-progress-in-precision-medicine/24177/



  
    Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism. 

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Managing Immune-Related Adverse Events With Immunotherapies

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Overcoming Barriers to Equitable Care in HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Download our free app to listen on your phone